Yogen Saunthararajah
0000-0002-9757-1031
Publication & Citation Trends
Publications
0 total
Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax
Cited by 0
Semantic Scholar
Chromodomain helicase DNA binding protein CHD2 interacts with TET2 and regulates lineage defining transcription in hematopoietic stem and progenitor cells
Cited by 0
Semantic Scholar
A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation
Cited by 0
Semantic Scholar
A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations
Cited by 0
Semantic Scholar
Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
Cited by 1
Semantic Scholar
Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis
Cited by 0
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(180)
Epigenetics and DNA Methylation
(109)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(46)
Hemoglobinopathies and Related Disorders
(40)
Histone Deacetylase Inhibitors Research
(31)
Affiliations
National Institutes of Health
Cleveland Clinic
Carolinas Healthcare System
The University of Texas MD Anderson Cancer Center
University of Illinois Urbana-Champaign